141eur
2,5 %
Date:2025-05-14Time:18:00:00Latest report:Q4-2023List:First NorthTicker:HRTIS
Market Cap:34 meurEnterprise Value:28 meurNet Sales:- meurEarnings:0,28 meurEmployees:0ISIN:FI4000087861

Ratios

10-year key figure history for Herantis Pharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Herantis Pharma with index and moving average MA50 and MA200.

Stockprice:1,41
MA50:1,39
MA200:1,45
Price/MA200:-2,6 %
RSI (14):54,7
Price/MA50:1,7 %

Description

Herantis Pharma is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. The company's lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. Herantis Pharma was founded in 2008 and has its headquarters in Espoo, Finland.

Biotechnology